3470-45-9Relevant articles and documents
Rational Design, Synthesis, and Pharmacological Characterization of Novel Ghrelin Receptor Inverse Agonists as Potential Treatment against Obesity-Related Metabolic Diseases
Daina, Antoine,Giuliano, Claudio,Pietra, Claudio,Wang, Junbo,Chi, Yushi,Zou, Zack,Li, Fugang,Yan, Zhonghua,Zhou, Yifan,Guainazzi, Angelo,Garcia Rubio, Silvina,Zoete, Vincent
supporting information, p. 11039 - 11060 (2018/10/24)
A new chemotype of ghrelin inverse agonists was discovered through chimeric design based on molecular scaffolds known as growth-hormone secretagogue receptor (GHSR) modulators but with divergent pharmacodynamic and pharmacokinetic properties. The structur
5H, 10H-IMIDAZO[1,2-A]INDENO[1,2-E] PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES
-
, (2008/06/13)
Compounds of formula (I), wherein R is a hydrogen atom or a carboxy, alkoxycarbonyl,--CO--NR 4 R 5,--PO 3 H 2 or--CH 2 OH radical, and R 1 is an-alk-NH 2,-alk-NH--CO--R 3,-alk-COOR 4,-alk-CO--NR 5 R 6 or--CO--NH--R 7 radical. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartame (NMDA) receptor and more specifically are ligands for NMDA receptor glycine modulator sites.